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Introduction {#sec1}
============

Macrophages are the first line of defense against invading pathogens, sensing through pathogen recognition receptors (PRRs) and initiating innate and adaptive responses. The most studied PRRs are Toll-like receptors (TLRs), expressed in monocytes, macrophages, and dendritic cells. They play a fundamental role in recognition of pathogen-associated molecular patterns expressed on infectious agents and subsequently initiate a series of inflammatory events that depend upon the MyD88 and/or TRIF signaling pathways ([@bib21]). The MyD88-dependent pathway is activated by all TLRs except TLR3 that signals only through TRIF. TLR4, however, activates both MyD88- and TRIF-dependent pathways in response to lipopolysaccharide (LPS), a component from the wall of gram-negative bacteria ([@bib34]); LPS-induced TLR4/TRIF-dependent signaling results in TBK1 activation, translocation of IRF3 into the nucleus, and type I IFN production, whereas MyD88-dependent signaling results in nuclear factor κB (NF-κB) translocation and expression of various pro-inflammatory genes ([@bib2], [@bib22]).

Macrophages, cells normally residing in a G0/terminally differentiated state, can re-enter the cell cycle into a G1-like phase, expressing certain cellular cell-cycle factors ([@bib29], [@bib30]), including cyclin-dependent kinase 1 (CDK1). This kinase is known to phosphorylate and deactivate the antiviral activity of SAMHD1 ([@bib10], [@bib49]), a deoxynucleotide-triphosphate (dNTP) hydrolase that restricts HIV-1 ([@bib3], [@bib16], [@bib20], [@bib24], [@bib25]). SAMHD1 phosphorylation at position T592 has been shown to be mediated by CDK1/2 ([@bib10], [@bib49]). Some argue that SAMHD1 phosphorylation at position T592 impairs its dNTP hydrolase activity and allows viral DNA synthesis to occur ([@bib3]), whereas others propose that T592 phosphorylation does not regulate SAMHD1 dNTPase activity and/or that T592 phosphorylation impacts dNTPase-independent restriction mechanisms ([@bib7], [@bib19], [@bib43], [@bib48], [@bib49]).

Type I interferons (IFNs) are known to arrest cycling cells ([@bib50], [@bib51]) and lead to dephosphorylation/activation of SAMHD1 in monocyte-derived macrophages (MDMs) ([@bib10], [@bib38]), although the mechanism is unclear. LPS has known potent inhibitory activity against HIV-1 infection ([@bib5], [@bib13], [@bib15], [@bib23], [@bib35], [@bib37], [@bib45]), partly due to downregulation of receptors for HIV-1 entry and impairment of early steps of the viral life cycle ([@bib13], [@bib44], [@bib46]). The mediators of HIV-1 suppression by LPS-stimulated MDMs are mostly secreted β-chemokines and IFNs ([@bib15], [@bib37], [@bib44], [@bib45]). However, some data suggest that IFN release by LPS-stimulated macrophages/dendritic cells might not be the main mediator of HIV-1 suppression ([@bib35], [@bib45]), although the underlying mechanism has not been elucidated.

Here we show that TLR4 activation by LPS and whole bacteria can regulate transition between G1 and G0 and SAMHD1 antiviral activity via a Myd88- and IFN-independent pathway. We show that the G1-to-G0 transition is downstream of TRIF but completely independent from TBK1 and IRF3 activation. The resulting G0 arrest is accompanied by p21 upregulation and SAMHD1 dephosphorylation. This demonstrates that TLR4 activation can directly induce G0 arrest in human macrophages independent of IFN secretion, while activating a pathogen defense program mediated by SAMHD1. This work adds to growing evidence that G0 arrest is a conserved and important response to danger signals even in cells classically viewed as being terminally differentiated.

Results {#sec2}
=======

TBK1- and IFN-Independent G0 Arrest following TLR4 Engagement by LPS Activates SAMHD1 Antiretroviral Activity {#sec2.1}
-------------------------------------------------------------------------------------------------------------

We have shown previously that macrophage transition from G0 to a G1-like state is accompanied by an increase in certain cell-cycle-associated proteins, such as MCM2 and CDK1, as well as phosphorylation of SAMHD1 at T592 that confers increased susceptibility to HIV-1 infection ([@bib29], [@bib30]). Although the cell-cycle state of macrophages *in vivo* is poorly defined, we demonstrated that two widely accepted *in vitro* MDM differentiation protocols that differ in what type of culture media is used can lead to differences in the proportion of MDMs in G1 ([Figure S1](#mmc1){ref-type="supplementary-material"}). MDMs differentiated in human serum (HS) are mainly in G0 (∼94%), and those differentiated in fetal calf serum (FCS) are predominantly in G1 (∼70%) ([Figure S1](#mmc1){ref-type="supplementary-material"}C), whereas hierarchical clustering of whole genome expression data showed that HS- and FCS-cultured MDMs cluster together and are distinct from closely related myeloid cells ([@bib29]). Further, in case of HS differentiation (mostly G0 MDMs), SAMHD1 is dephosphorylated/active. In case of FCS differentiation (MDMs mostly in G1), SAMHD1 is phosphorylated/inactive ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1F--S1H). In the present study, we used the FCS differentiation protocol ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Treatment with 10 ng/mL LPS for 18 h resulted in a decrease of MCM2 and CDK1 expression and as expected, SAMHD1 dephosphorylation at T592 ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}I--S1K). These results suggest that LPS treatment led to G1-to-G0 transition (∼G0 arrest) in macrophages where SAMHD1 is activated and can block HIV-1 infection as shown in [Figure 1](#fig1){ref-type="fig"}A. Of note, HS-differentiated macrophages behaved in a similar way following LPS exposure ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Crucially, the TLR4 inhibitor TAK242 completely prevented G0 arrest and SAMHD1 phosphorylation changes, restoring HIV-1 infection ([Figures 1](#fig1){ref-type="fig"}A--1C). Blocking IFN signaling in macrophages by treatment with the JAK1/2 inhibitor ruxolitinib (RUXO) could not prevent G1-to-G0 transition, demonstrating that LPS-induced G0 arrest and SAMHD1 dephosphorylation/activation in human macrophages via TLR4 is IFN independent.Figure 1TLR4 Activation Induces G0 Arrest, Dephosphorylates SAMHD1, and Blocks HIV-1 Infection in an Interferon-Independent Manner(A) MDMs were treated with TAK242, BX795, and RUXO 6 h before addition of LPS. Cells were infected by vesicular stomatitis virus G protein (VSV-G)-pseudotyped HIV-1 18 h later. The percentage of infected cells was determined 48 h post-infection (n = 5, mean ± SEM). Cells from a representative donor were used for immunoblotting.(B) A simplified diagram of TLR4 signaling in response to LPS. LPS activates both MyD88-dependent and -independent signaling pathways. BX795, an inhibitor of TBK1; RUXO (ruxolitinib), an inhibitor of JAK1/2 kinase that suppresses IFN signaling; TAK242, an inhibitor of TLR4 signaling.(C) IRF3/NF-κB nuclear translocation assay. Cells were exposed to LPS in the absence or presence of TAK242, BX795, and RUXO, and 2 h later stained for IRF3/NF-κB. The percentage of cells with nuclear staining was determined (n = 3, mean ± SEM). Scale bars, 20 μm.(D) Expression data of TRIF and TBK1 in MDMs, displayed as cycle threshold (Ct) values (n = 3, mean ± SEM).(E--H) MDMs were transfected with control or TRIF, TBK1 siRNA. mRNA expression is shown as fold change relative to control (n = 3, mean ± SEM) (E). Cells from a representative donor were used for immunoblotting (F). Cells were exposed to LPS in control or KD cells, and 2 h later stained for IRF3/NF-κB. % of cells with nuclear staining was determined (n = 3, mean ± SEM) (G). MDMs transfected with control or TRIF, TBK1 siRNA were treated with LPS. Cells were infected by VSV-G-pseudotyped HIV-1 18 h later. The percentage of infected cells was determined 48 h post-infection (n = 3 donors, mean ± SEM). Cells from a representative donor were used for immunoblotting (H).^∗∗∗^p ≤ 0.001; ^∗∗^p ≤ 0.01; *^∗^*p ≤ 0.1; ^ns^p, non-significant, paired t test.

We next used the TBK1 inhibitor BX795 that blocks phosphorylation, nuclear translocation, and transcriptional activity of IRF3. This drug successfully prevented IRF3 translocation to the nucleus ([Figure 1](#fig1){ref-type="fig"}C), but could not prevent G1-to-G0 transitioning, SAMHD1 dephosphorylation, and blockade of HIV-1 infection ([Figures 1](#fig1){ref-type="fig"}A--1C). Similarly, TBK1 knockdown (KD) was unable to prevent G1-to-G0 transitioning ([Figures 1](#fig1){ref-type="fig"}D--1H). By contrast, depletion of TRIF did prevent G1-to-G0 transitioning ([Figures 1](#fig1){ref-type="fig"}D--1H), revealing that G0 arrest following TLR4 activation is downstream of TRIF but upstream of TBK1 signaling ([Figures 1](#fig1){ref-type="fig"}B and 1D--1H).

MyD88 Activation via TLR4 or TLR5 Does Not Induce G0 Arrest {#sec2.2}
-----------------------------------------------------------

Tenascin-C (TNC) is an extracellular matrix protein rapidly induced at the site of infection or injury, where it triggers inflammation by activating TLR4 in different cells, including macrophages ([@bib28]). This TLR4 activation is specifically mediated through the MyD88-dependent pathway ([@bib27]) ([Figure 2](#fig2){ref-type="fig"}A). Flagellin (FLA) is the main component of bacterial flagellum. It binds to TLR5 and induces MyD88-dependent signaling. Both TNC and FLA effectively activated the MyD88-dependent pathway in MDMs, which was confirmed by detectable translocation of NF-κB and production of cytokines (interleukin-6 \[IL-6\], IL-8) into culture media, but absence of nuclear IRF3 and CXCL10 production ([Figures 2](#fig2){ref-type="fig"}B and 2C). Importantly, when MDMs were treated with TNC or FLA, no changes to cell-cycle protein expression, SAMHD1 phosphorylation, or HIV-1 inhibition were detected ([Figure 2](#fig2){ref-type="fig"}D). From these experiments we conclude that MyD88 activation is insufficient to induce G0 arrest, dephosphorylation of SAMHD1, and blockade of HIV-1 infection.Figure 2TLR4-Mediated Activation of SAMHD1 Is MyD88 Independent(A) Diagram of TLR4 activation. LPS activates both MyD88-dependent and -independent signaling pathways. Tenascin-C (TNC) and Flagellin (FLA) activate only the MyD88-dependent pathway leading to NF-κB translocation into the nucleus.(B) IRF3/NF-κB translocation assay. Cells were exposed to TNC, FLA, and LPS and 2 h later stained for IRF3/NF-κB. The percentage of cells with nuclear staining was determined (n = 3, mean ± SEM). Scale bars, 20 μm.(C) MDMs were treated with LPS, TNC, and FLA, and cytokines were measured by ELISA in culture media 24 h later.(D) MDMs treated with TNC, FLA, and LPS were infected by VSV-G-pseudotyped HIV-1 18 h later. The percentage of infected cells was determined 48 h post-infection (n = 3, mean ± SEM). Cells from a representative donor were used for immunoblotting.^∗∗∗^p ≤ 0.001; *^∗∗^*p ≤ 0.01; ^ns^p, non-significant, paired *t*-test.

LPS Activation of TLR4 Results in IFN-Independent Upregulation of p21 {#sec2.3}
---------------------------------------------------------------------

We hypothesized that the LPS-induced IFN-independent G0 arrest would be regulated by expression of negative cell-cycle regulators, such as p16, p21, or p27. Immunoblots performed in the presence of RUXO to block IFN-dependent signaling confirmed that the decrease in CDK1 and MCM2 after LPS treatment was accompanied by increased p21 levels ([Figure 3](#fig3){ref-type="fig"}A). Because we were unable to detect p27 or p16 expression in immunoblot, we next sought to further characterize the cell-cycle program changes triggered by LPS in MDMs, using a panel of cell-cycle-associated transcripts measured by qPCR ([Figures 3](#fig3){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A--S2D). Statistically significant decreases compared with the untreated control (set to 1) were observed in the following transcripts associated with cell-cycle progression: CDK1; MCM2; and cyclins E2, B1, E1, A2, and E2F1. A significant increase was observed for p21 transcript associated with cell-cycle arrest ([Figure 3](#fig3){ref-type="fig"}C, far right panel). The full panel of transcripts is shown in [Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D. It has been suggested that production of reactive oxygen species (ROS) or DNA damage during LPS treatment can activate p21 pathway and cell-cycle arrest in proliferating cells ([@bib9], [@bib33]). In our study, exposure to LPS led to increased p21 expression, but not to markers associated with DNA damage, such as γH2AX and 53BP1 ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). LPS triggered ROS production ([Figure S3](#mmc1){ref-type="supplementary-material"}E) that could be inhibited by using *N*-acetyl-cysteine (NAC). Nevertheless, this inhibition had no effect on LPS-mediated G0 arrest ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Our data thus suggest that ROS or DNA damage is unlikely to be responsible for G0 arrest in human MDMs.Figure 3Cell-Cycle Profiling of MDMs following TLR4 Activation and Demonstration that SAMHD1 Mediates the Interferon-Independent Blockade of HIV Infection(A) MDMs were treated with RUXO 6 h before addition of LPS. Cells from a representative donor were used for immunoblotting 18 h later to detect changes in cell-cycle-associated proteins.(B) A heatmap depicts differential gene expression patterns of cell-cycle-associated transcripts in MDMs treated with LPS in the presence of RUXO in three donors. The color scale bar corresponds to log-fold expression.(C) Relative expression levels (fold changes) of statistically significantly changed cell-cycle-associated transcripts after LPS in the presence of RUXO (n = 4 donors, mean ± SEM).(D and E) MDMs were transfected with control or pool of SAMHD1 siRNAs (KD) and 3 days later treated with RUXO and followed 6 h after that with LPS. Cells were infected in the presence of LPS with VSV-G-pseudotyped HIV-1 GFP 18 h later. The percentage of infected cells was quantified 48 h post-infection. SAMHD1 KD in four different donors. Error bars represent technical triplicates (D). Cells from a representative donor were used for immunoblotting (E).(F) Immunoblot of SIV virus-like particles (VLPs). delX, SIV VLP with deleted Vpx; E16A, SIV VLP containing mutated Vpx (E16A mutant Vpx does not bind SAMHD1); WT, SIV VLP containing wild-type Vpx.(G) SAMHD1 degradation in MDMs by SIV VLPs. Equal quantities of SIV VLPs were added to macrophages. Cells from a representative donor were used for immunoblotting.(H) MDMs were treated ± LPS and infected by VSV-G-pseudotyped HIV-1 in the presence of different SIV VLPs (as indicated). The percentage of infected cells was determined 48 h post-infection (n = 4 donors, mean ± SEM).(I) Diagram of G0 arrest following TLR4/TRIF activation resulting in block to HIV-1 infection.^∗∗∗^p ≤ 0.001; ^∗∗^p ≤ 0.01; *^∗^*p ≤ 0.1; ^ns^p, non-significant, paired t test.

Redundancy of Pathways Activated by TLR4 that Lead to G0 Arrest {#sec2.4}
---------------------------------------------------------------

IFN as a cause of cell-cycle arrest has been reported in myeloid cells from mice and murine cell lines, as well as in human cell lines ([@bib11], [@bib50], [@bib51]), monocytes, and T cells ([@bib31]). We next examined the effect of blocking IFN signaling after TLR4 activation, as well as after addition of exogenous IFNβ ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2F). RUXO, an inhibitor of JAK kinases and IFN signaling, was used to treat MDM 6 h before addition of LPS or IFNβ. As expected, RUXO completely blocked expression of selected interferon stimulated genes (ISGs), CXCL10, MxA, ISG 54, and ISG 56, after both LPS and IFNβ treatment, confirming that IFN signaling is inhibited in both conditions ([Figures S2](#mmc1){ref-type="supplementary-material"}C).

Although G0 arrest was observed after both LPS and exogenous IFNβ addition, based on expression levels of cell-cycle-associated transcripts and protein expression of cell-cycle marker MCM2, RUXO was unable to rescue this arrest caused by LPS/TLR4 activation but completely rescued G0 arrest after addition of exogenous IFNβ ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2E). This confirms redundancy of pathways activated by TLR4 that lead to G0 arrest. In concordance with these results, RUXO failed to restore HIV-1 infection from the effect of LPS but completely rescued HIV-1 infection after exposure to exogenous IFNβ ([Figure S2](#mmc1){ref-type="supplementary-material"}E). These data were confirmed by using an IFN receptor antibody instead of RUXO ([Figure S2](#mmc1){ref-type="supplementary-material"}F). As a control, the TLR4 inhibitor TAK242 prevented G0 arrest and restored HIV-1 infection after LPS treatment. As expected, TAK242 could not rescue either after IFNβ treatment. We conclude the existence of two independent pathways that are responsible for G0 arrest in MDMs, both of which are able to potently block HIV-1 infection. The first and early block of HIV-1 infection is via G0 arrest, whereas IFN production represents a second wave.

SAMHD1 Is Directly Responsible for the IFN-Independent HIV-1 Blockade following TLR4 Activation {#sec2.5}
-----------------------------------------------------------------------------------------------

We have shown previously that the restriction of HIV-1 infection in G0 MDMs can be completely lifted by SAMHD1 depletion ([@bib29]). In the present study, the experimental system involves use of MDMs predominantly in G1-like state, where SAMHD1 is deactivated/phosphorylated at T592. To confirm that LPS-mediated SAMHD1 activation/dephosphorylation is responsible for block to HIV-1 infection during IFN-independent G0 arrest, we employed SAMHD1 KD in the presence of RUXO to inhibit the effects of any secreted IFN ([Figures 3](#fig3){ref-type="fig"}D and 3E). We knocked down SAMHD1 expression in human MDMs using small interfering RNA (siRNA) and infected MDMs in the presence or absence of LPS in four different donors ([Figures 3](#fig3){ref-type="fig"}D and 3E). SAMHD1 KD lifted HIV-1 block in the presence of LPS. Immunoblot confirmed 80% SAMHD1 KD with no effect on the cell-cycle marker MCM2 ([Figure 3](#fig3){ref-type="fig"}E).

In order to confirm the role of SAMHD1, we employed Vpx, an accessory protein encoded by lentiviruses such as HIV-2 and simian immunodeficiency virus (SIV), but not HIV-1 ([@bib20], [@bib24]). Vpx degrades SAMHD1 in a DCAF-dependent fashion ([@bib20]). We exposed MDMs to LPS and co-infected cells 18 h later with HIV-1 and SIVmac virus-like particles (SIV VLPs) bearing Vpx (wild-type \[WT\], degrades SAMHD1), no Vpx present (delX, no SAMHD1 degradation), and E16A Vpx mutant that fails to interact with SAMHD1 ([@bib1]) (E16A, no SAMHD1 degradation) ([Figures 3](#fig3){ref-type="fig"}F and 3G). When MDMs were exposed to LPS and infected with HIV-1, only cells where SAMHD1 was exogenously depleted by co-infection with SIV VLP WT were fully susceptible to infection ([Figure 3](#fig3){ref-type="fig"}H). These data highlight the key role that SAMHD1 plays in the TLR4-mediated IFN-independent antiretroviral state in human macrophages ([Figure 3](#fig3){ref-type="fig"}I).

Whole Gram-Negative Bacteria Induce IFN-Independent G0 Arrest in Human MDMs {#sec2.6}
---------------------------------------------------------------------------

We employed pHrodo *E. coli* BioParticles to activate TLR4 by whole *E. coli* bacteria. BioParticles were incubated with MDMs in the presence or absence of different inhibitors for 1 h at 37°C ([Figure 4](#fig4){ref-type="fig"}A). Unbound pHrodo was washed off, and macrophages were incubated overnight. Cell supernatants were then collected for cytokine detection ([Figure S4](#mmc1){ref-type="supplementary-material"}A), and MDMs were infected with HIV-1. First, phagocytosis of pHrodo was unaffected by the presence of TLR4, JAK1/2, or TBK1 inhibitors ([Figure 4](#fig4){ref-type="fig"}A). Second, binding/ingestion of pHrodo triggered expression of tumor necrosis factor alpha (TNF-α), IL-6, and IL-8 that was abrogated after TLR4 inhibition, but not by inhibition of the IFN signaling pathway ([Figure S4](#mmc1){ref-type="supplementary-material"}A). This was confirmed by IRF3 and NF-κB translocation assays ([Figure 4](#fig4){ref-type="fig"}B). These data show that pHrodo triggers a robust immune response in MDMs that can be prevented by TLR4 inhibition. Treatment of MDMs with pHrodo induced potent HIV-1 inhibition that was accompanied by G0 arrest and SAMHD1 activation/dephosphorylation at T592 ([Figures 4](#fig4){ref-type="fig"}C and 4D). Importantly, TLR4 blockade was able to prevent G0 arrest, SAMHD1 dephosphorylation, and HIV-1 blockade, but neither RUXO nor TBK1 inhibitor BX795 could achieve this, phenocopying experiments with LPS alone ([Figure 1](#fig1){ref-type="fig"}). However, when we measured cell-cycle-associated transcripts there were several differences between LPS- and *E. coli*-mediated TLR4 activation, mostly connected to negative regulators of cell cycle. p16 and WIF1 were significantly increased, but no change was detected for p21 ([Figures 4](#fig4){ref-type="fig"}E, 4F, and [S4](#mmc1){ref-type="supplementary-material"}B). These data show that gram-negative bacteria can induce IFN-independent G0 arrest and SAMHD1 dephosphorylation/activation in human macrophages ([Figure 4](#fig4){ref-type="fig"}G).Figure 4TLR4 Activation by Whole *E. coli* Induces Interferon-Independent G0 Arrest(A) pHrodo-labeled *E. coli* were added to MDMs for 1 h. MDMs were washed and fixed. 10^4^ cells were recorded and analyzed. Percentage of *E. coli*-positive cells was determined using automated cell imaging system Hermes WiScan and ImageJ.(B) IRF3/NF-κB translocation assay. Cells were exposed to pHrodo *E. coli* in the presence or absence of inhibitors and 2 h later stained for IRF3/NF-κB. The percentage of cells with nuclear staining was determined (n = 3, mean ± SEM). No IRF3 or NF-κB translocation was detected in un-treated cells.(C and D) MDMs were treated with (C) TAK242 or RUXO 6 h or (D) BX795 2 h before addition of pHrodo *E. coli*. Cells were infected by VSV-G-pseudotyped HIV-1 18 h later. The percentage of infected cells was determined 48 h post-infection (n = 3 donors, mean ± SEM). Cells from a representative donor were used for immunoblotting.(E and F) Relative expression levels (fold changes) of ISGs (E) and cell-cycle-associated transcripts (F). MDMs were treated with RUXO 6 h before addition of pHrodo *E. coli*. Cells were collected 24 h later (n = 3 donors, mean ± SEM).(G) Diagram of G0 arrest following exposure to *E. coli* and TLR4/TRIF activation resulting in block to HIV-1 infection.^∗∗∗^p ≤ 0.001; *^∗∗^*p ≤ 0.01; *^∗^*p ≤ 0.1, paired t test.

Discussion {#sec3}
==========

Here we have shown that macrophages respond to gram-negative bacteria not only by activating the canonical TLR4 pathways involving NF-κB and IRF3, but also by a pathway independent of TBK1 and IRF3, culminating in p21 upregulation and G0 arrest. This previously unrecognized pathway is not dependent or sensitive to blockade of the type I IFN/JAK-STAT signaling axis. Activation of the pathway leads to dephosphorylation of SAMHD1 at a T592 and a specific block to HIV-1 infection that is significantly counteracted by SAMHD1 depletion. Importantly, we have also shown that TLR4 activation by whole *E. coli* bacteria also leads to a similar IFN-independent G0 arrest in human macrophages.

The effect of LPS on cell cycle has been reported in mouse primary cells and murine cell lines ([@bib42], [@bib52]) or in the human cell line, THP-1/U937 ([@bib33], [@bib39]). Despite these reports, surprisingly little is known about the mechanism how LPS causes cell-cycle arrest. It has been reported that LPS treatment leads to p21 pathway activation and cell-cycle arrest in monocytic THP-1 ([@bib33]). In addition, LPS exposure has been linked to ROS production, subsequent DNA damage, and upregulation of p21 expression in monocytes and fibroblasts ([@bib9], [@bib33]). Despite these reports, our data show that neither ROS nor DNA damage seem to be associated with G0 arrest in human MDMs ([Figure S3](#mmc1){ref-type="supplementary-material"}). Another possibility is that strong TLR4 activation triggers an apoptotic program in the cells, and cell-cycle arrest is the first step to apoptosis and cell death ([@bib12]). However, our data do not support this hypothesis because no significant reduction in cell numbers was observed up to 5 days post-LPS treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}G), suggesting survival of activated macrophages. Furthermore, we observed increased levels of p21 after LPS treatment, and p21 has been reported to play an antiapoptotic role ([@bib4], [@bib14], [@bib26]). Increased expression of p21 might thus lead to G0 arrest but at the same time prevent apoptosis.

Why would macrophages regulate their cell cycle in response to bacteria? Macrophages are secretory cells vital to the regulation of immune responses and development of inflammation. Even though our previous work showed that MDMs enter G1 without measurable cell division ([@bib29]), many tissue resident macrophages can proliferate ([@bib17]). One can imagine that cell division of macrophages would benefit the host by increasing the number of effector cells at the center of infection. However, the division of infected cells harboring live pathogen could also lead to doubling of infected cells, an event that can potentially harm the host. Therefore, we speculate that this early cell arrest could be a mechanism for limiting local invasion of gram-negative bacteria into macrophages.

It is also possible that cell-cycle changes are necessary for activation of alternative functions of cell-cycle-associated proteins. G0 or cell-cycle arrested cells will increase expression of p14, p16, p21, or p27 proteins, for example. It has been shown that p21 can suppress IL-1β ([@bib36]), or that p16 inhibits macrophage activity by degradation of IL-1 receptor and thus impairs IL-6 production ([@bib32]). In addition, previous studies have shown that deficiency in p21 renders mice more susceptible to septic shock ([@bib36], [@bib40]); therefore, cell arrest may be a mechanism for limiting production of potentially harmful cytokines.

The relevance of macrophage G0 arrest by LPS may be relevant in HIV pathogenesis, where macrophages will be exposed to gut-derived LPS during inflammation in the acute or chronic phase of HIV. It has been shown that circulating LPS is increased in chronically HIV-1-infected individuals and SIV-infected non-human primates ([@bib8]). Exploring LPS-mediated regulation in primary human macrophages is therefore important for our understanding of HIV-1 replication and cellular reservoirs ([@bib47]).

Our study is based on primary MDMs rather than tissue-derived macrophages, such as those in lymph nodes, gut, or central nervous system. We utilized a differentiation protocol that led to high proportions of macrophages in G1 in order to be able to clearly study the effect of LPS on cell cycle. Although we previously reported 10%--20% of *ex vivo* peritoneal mouse macrophages and microglial cells to be in G1 ([@bib29]), it is difficult to know the proportions of macrophages in G1 across diverse human tissues. Even if 10%--20% of macrophages *in vivo* are in G1, this is nonetheless significant, and LPS responses in these cells warrant specific characterization.

In summary, our data show that TLR4 activation by LPS or whole bacteria regulates the cell cycle in human primary macrophages through a non-canonical mechanism that is TRIF dependent. This culminates in G0 arrest and activation of the antiviral protein SAMHD1, suggesting that macrophages can rapidly achieve a heightened state of alert in response to gram-negative bacteria prior to type I IFN secretion. Finally, given that macrophage G0 arrest occurs following DNA damage ([@bib30]), histone deacetylase (HDAC) inhibition ([@bib29]), and immune stimuli, we conclude that cell-cycle regulation appears to be a conserved and important response to danger signals in human macrophages.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit Anti-Human SAMHD1 Polyclonal AntibodyProteintechCat\# 12586-1-AP, RRID:[AB_2183496](nif-antibody:AB_2183496){#intref0010}Mouse Anti-Actin, beta Monoclonal AntibodyAbcamCat\# ab6276, RRID:[AB_2223210](nif-antibody:AB_2223210){#intref0015}Rabbit polyclonal CDK1 AntibodyBethylCat\# A303-664A, RRID:[AB_11204758](nif-antibody:AB_11204758){#intref0020}Mouse Anti-BM28 Monoclonal AntibodyBD BiosciencesCat\# 610701, RRID:[AB_398024](nif-antibody:AB_398024){#intref0025}Phospho-SAMHD1 (Thr592) (D7O2M) Rabbit mAb antibodyCell Signaling TechnologyCat\# 89930, RRID:[AB_2800147](nif-antibody:AB_2800147){#intref0030}Mouse Anti-P21 Monoclonal antibody, Unconjugated, Clone f-5Santa Cruz BiotechnologyCat\# sc-6246, RRID:[AB_628073](nif-antibody:AB_628073){#intref0035}IRF-3 (D6I4C) XP® antibodyCell Signaling TechnologyCat\# 11904, RRID:[AB_2722521](nif-antibody:AB_2722521){#intref0040}NFkappaB p65 (F-6) antibodySanta Cruz BiotechnologyCat\# sc-8008, RRID:[AB_628017](nif-antibody:AB_628017){#intref0045}Purified anti-H2A.X Phospho (Ser139) antibodyBioLegendCat\# 613402, RRID:[AB_315795](nif-antibody:AB_315795){#intref0050}53BP1 antibodyBD BiosciencesCat\# 612522, RRID:[AB_2206766](nif-antibody:AB_2206766){#intref0055}Anti-IFNα/β ReceptorPBL Interferon SourceN/AMouse IgG2A Isotype Control (Clone 20102) antibodyR and D SystemsCat\# MAB003, RRID:[AB_357345](nif-antibody:AB_357345){#intref0060}Rat Anti-IL-6 Monoclonal Antibody, Unconjugated, Clone MQ2-13A5BD BiosciencesCat\# 554543, RRID:[AB_398568](nif-antibody:AB_398568){#intref0065}Mouse Anti-IL-8 Monoclonal Antibody, Unconjugated, Clone G265-5BD BiosciencesCat\# 554716, RRID:[AB_395526](nif-antibody:AB_395526){#intref0070}Mouse Anti-TNF Monoclonal Antibody, Unconjugated, Clone MAb1BD BiosciencesCat\# 551220, RRID:[AB_394098](nif-antibody:AB_394098){#intref0075}Rabbit Anti-Human TICAM1 Polyclonal Antibody, UnconjugatedGeneTexCat\# GTX104744, RRID:[AB_1241389](nif-antibody:AB_1241389){#intref0080}TBK1 AntibodyBethylCat\# A300-093A, RRID:[AB_2303002](nif-antibody:AB_2303002){#intref0085}**Bacterial and Virus Strains**VSV-G HIV-1 GFP virus[@bib6]N/ASIVmac Virus like particles[@bib18], [@bib35]N/A**Biological Samples**PBMC from HIV seronegative donorsThis studyN/A**Chemicals, Peptides, and Recombinant Proteins**AB Human SerumSigma\#H4522FBSBioseraN/ABX795APEXBIO\#A8222RuxolitinibCell guidance system\#SM87Recombinant human IFN-bPeprotech\#300-02BCRecombinant human Tenascin CR and D\#3358-TC-050Polymyxin BSigma\#P4932LPSInvivoGen\#tlrl-prslpsTAK242Milllipore\#614316Recombinant Flagellin proteinAbcam\#Ab201366DMEM, high glucose, pyruvateInvitrogen\#41966052RPMI 1640 mediumInvitrogen\#21875091Opti-MEMInvitrogen\#31985047Fugene HD transfection reagentPromega\#E2311DAPISigma\#10236276001PhosSTOPSigma\#4906845001Fast SYRB green master mixThermoFisher\#4385610Total RNA Purification KitNorgen\#17200**Critical Commercial Assays**CellRoxMolecular Probes\#C10444NuPAGE 4-12% Bis-Tris Protein GelInvitrogen\#NP0322BOXpHrodo E.coli BioParticlesThermoFisher\#P35361SuperScript III First-Strand Synthesis SystemThermoFisher\#18080051Amersham ECL Prime Western Blotting Detection ReagentGE Healthcare\#RPN2232**Experimental Models: Cell Lines**293TLaboratory of G. Towers (UCL)N/A**Oligonucleotides**CDK1 FWD\
5′TGAGGAACGGGGTCCTCTAA 3′InvitrogenN/ACDK1 R 5′ A TGGCT ACCACTTGA\
CCTGT 3′InvitrogenN/ACDK2 F 5′ AAGTTGACGGGAGAG\
GTGGT 3′InvitrogenN/ACDK2 R 5′ TGATGAGGGGAAGAG\
GAATG 3′InvitrogenN/ACDK4 F 5′ CAGATGGCACTTACACCCGT 3′InvitrogenN/ACDK4 R 5′ CAGCCCAATCAGGTC\
AAAGA 3′InvitrogenN/ACDK6 F 5′ CGTGGTCAGGTTGTT\
TGATGT 3′InvitrogenN/ACDK6 R 5′ CGGTGTGAATGAAGAA\
AGTCC 3′InvitrogenN/ACyclin A2 F 5′ AAGACGAGACGGGTTGC 3′InvitrogenN/ACyclin A2 R 5′\
GGCTGTTTACTGTTTGCTTTCC 3′InvitrogenN/ACyclin B1 F 5′\
TTCTGGATAATGGTGAATGGAC 3′InvitrogenN/ACyclin B1 R 5′\
ATGTGGCATACTTGTTCTTGAC 3′InvitrogenN/ACyclin D1 F 5′\
AGATGAAGGAGACCATCCCCC 3′InvitrogenN/ACyclin D1 R 5′\
CCACTTGAGCTTGTTCACCA 3′InvitrogenN/ACyclin D3 F 5′ GGCCGGGGACCGAAACT 3′InvitrogenN/ACyclin D3 R\
5′CAGTGGCGAAGTGTTTACAAAGT 3′InvitrogenN/ACyclin E1 F 5′\
CCGGTATATGGCGACACAAG 3′InvitrogenN/ACyclin E1 R 5′\
TACGCAAACTGGTGCAACTT 3′InvitrogenN/ACyclin E2 F 5′\
TCTCCTGGCTAAATCTCTTTCTCC 3′InvitrogenN/ACyclin E2 R 5′\
ACTGTCCCACTCCAAACCTG 3′InvitrogenN/AE2F1 F 5′ TGCCAAGAAGTCCAAGA\
ACCA 3′InvitrogenN/AE2F1 R 5′ GTCAACCCCTCAAGCCGTC 3′InvitrogenN/AE2F4 F 5′ CGGACCCAACCCTTCT ACCT 3′InvitrogenN/AE2F4 R 5′ GGGGCAAACACTTCTGAGGA 3′InvitrogenN/AE2F7 F 5′ CCTTTAGCCCACCCAGTATTT 3′InvitrogenN/AE2F7 R 5′ A TCCCTCTCTGACCCTGACC 3′InvitrogenN/AMCM2 F 5′CACCCGAAGCTCAACCA\
GAT 3′InvitrogenN/AMCM2 R 5′ATCATGGACTCGATGTG\
CCG 3′InvitrogenN/ARB1 F 5′AAAGGACCGAGAAGGACCA 3′InvitrogenN/ARB1 R 5′AAGGCTGAGGTTGCTTGTGT 3′InvitrogenN/AWIF1 F 5′TCTGTTCAAAGCCTGTCTGC 3′InvitrogenN/AWIF1 R 5′ACATTGGCATTTGTTGGGTT 3′InvitrogenN/Ap14 F 5′GAGTGAGGGTTTTCGTGGTTC 3′InvitrogenN/Ap14 R 5′ACGGGTCGGGTGAGAGTG 3′InvitrogenN/Ap16 F 5′ CGGCTGACTGGCTGGC 3′InvitrogenN/Ap16 R 5′ GGGTCGGGTGAGAGTGG3′InvitrogenN/Ap21 F 5′GCCGAAGTCAGTTCCTTGTG 3′InvitrogenN/Ap21 R 5′TCGAAGTTCCATCGCTCACG 3′InvitrogenN/Ap27 F 5′A TGTTTCAGACGGTTCCCCA 3′InvitrogenN/Ap27 R 5′TCCAACGCTTTTAGAGGCAG 3′InvitrogenN/Ap53 F 5′AAGTCTAGAGCCACCGTCCA 3′InvitrogenN/Ap53 R\
5′TTTCAGGAAGTAGTTTCCATAGGT 3′InvitrogenN/ACXCL10 F 5′ TGGCATTCAAGGAGTACC\
TC 3′SigmaN/ACXCL10 R 5′\
TTGTAGCAATGATCTCAACACG 3′SigmaN/AISG56 F 5′CCT CCT TGG GTT CGT CTA\
CA 3′SigmaN/AISG56 R 5′GGC TGA TAT CTG GGT GCC\
TA 3′SigmaN/AISG54 F 5′CAGCTGAGAATTGCACTGC\
AA 3′SigmaN/AISG54 R 5′CGT AGGCTGCTCTCCAAG\
GA 3′SigmaN/AMxA F 5′ATC CTG GGA TTT TGG GGC\
TT 3′SigmaN/AMxA R 5′CCG CTT GTC GCT GGT GTC G 3′SigmaN/ASAMHD1 F\
5′TTGTGCTAGAGATAAGGAAGTTGG 3′InvitrogenN/ASAMHD1 R\
5′TGTGTTGATAAGCTCTACGGTG 3′InvitrogenN/AGAPDH F 5′ACC CAG AAG ACT GTG GAT\
GG 3′SigmaN/AGAPDH R 5′TTC TAG ACG GCA GGT CAG\
GT 3′SigmaN/AON-TARGETplus Human SAMHD1 siRNADharmacon\#L-013950-01Control siRNASanta Cruz\#sc-37007TBK1 siRNASanta Cruz\#sc-39058TICAM1 siRNAOriGene\#SR315629**Recombinant DNA**GFP-encoding genome CSGWLaboratory of G. TowersN/Ap8.91Laboratory of G. TowersN/ApMDGLaboratory of G. TowersN/ASIVmac packaging plasmid encoding\
accessory genesLaboratory of G. TowersN/ApCDNA Vpx E16ALaboratory of J. Luban, [@bib35]N/A**Software and Algorithms**ImageJ<https://imagej.nih.gov/ij/>**Other**Amersham Hybond P 0.45 PVDF blotting\
membraneGE Healthcare\#10600023

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Prof. Ravi Gupta (<rkg20@cam.ac.uk>).

This study did not generate unique new reagents.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell lines and viruses {#sec4.3.1}

293T cells were cultured in DMEM complete (DMEM supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS). VSV-G HIV-1 GFP virus was produced by transfection of 293T with GFP-encoding genome CSGW, packaging plasmid p8.91 and pMDG as previously described ([@bib6]). SIVmac Virus like particles (VLP) containing Vpx were prepared as previously described ([@bib18], [@bib35]).

### Monocyte isolation and differentiation {#sec4.3.2}

PBMC were prepared from HIV seronegative male and female donors (after informed consent was obtained), by density-gradient centrifugation (Lymphoprep, Axis-Shield, UK). Monocyte-derived macrophages (MDM) were prepared by adherence with washing of non-adherent cells after 2h, with subsequent maintenance of adherent cells in RPMI 1640 medium supplemented with 10% human serum and MCSF (10ng/ml) for 3 days and then differentiated for a further 4 days in RPMI 1640 medium supplemented with 10% fetal calf sera without M-CSF.

### Ethics Statement {#sec4.3.3}

Adult subjects provided written informed consent. Primary Macrophage & Dendritic Cell Cultures from Healthy Volunteer Blood Donors has been reviewed and granted ethical permission by the National Research Ethics Service through The Joint UCL/UCLH Committees on the Ethics of Human Research (Committee Alpha) 2nd of December 2009. Reference number 06/Q0502/92.

Method Details {#sec4.4}
--------------

### Infection of primary cells using full-length and VSV-G pseudotyped HIV-1 viruses {#sec4.4.1}

GFP containing VSV-G pseudotyped HIV-1 was added to MDM and after 4h incubation removed and cells were washed in culture medium. The percentage of infected cells was determined 48h post-infection by Hermes WiScan automated cell-imaging system (IDEA Bio-Medical Ltd. Rehovot, Israel) and analyzed using MetaMorph and ImageJ software. In the experiments when LPS was used cells were stimulated with 10ng/ml of LPS 18h before infection unless stated otherwise. 10^4^ cells were recorded and analyzed.

### SDS-PAGE and Immunoblots {#sec4.4.2}

Cells were lysed in reducing Laemmli SDS sample buffer containing PhosSTOP (Phosphatase Inhibitor Cocktail Tablets, Roche, Switzerland) at 96°C for 10 minutes and the proteins separated on NuPAGE® Novex® 4%--12% Bis-Tris Gels. Subsequently, the proteins were transferred onto PVDF membranes (Millipore, Billerica, MA, USA), the membranes were quenched, and proteins detected using specific antibodies. Labeled protein bands were detected using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare, USA) and Amersham Hyperfilm or AlphaInnotech CCD camera. Protein band intensities were recorded and quantified using AlphaInnotech CCD camera and AlphaView software (ProteinSimple, San Jose, California, USA).

### SAMHD1 knock-down by siRNA {#sec4.4.3}

1x10e5 MDM differentiated in MCSF for 4 days were transfected with 20pmol of siRNA (L-013950-01, Dharmacon) using *Lipofectamine RNAiMAX* Transfection Reagent (Invitrogen). Transfection medium was replaced after 18h with RPMI 1640 medium supplemented with 10% FCS and cells cultured for additional 3 days before infection.

### Quantitative PCR {#sec4.4.4}

Total RNA was isolated from macrophages using the Total RNA Purification Kit from Norgen Biotek (Thorold, Canada). cDNA was synthesized using Superscript III Reverse Transcriptase (Thermo Fisher Scientific) using 500ng of template RNA. qPCR was performed on ABI 7300 machine (Thermo Fisher Scientific) using Fast SYRB green master mix (Thermo Fisher Scientific). Expression levels of target genes were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as previously described ([@bib41]). See primer sequences in [STAR Methods](#sec4){ref-type="sec"}.

### Immunofluorescence {#sec4.4.5}

MDMs were fixed in 3% PFA, quenched with 50 mM NH~4~Cl and permeabilized with 0.1% Triton X-100 in PBS or 90% Methanol. After blocking in PBS/1% FCS, MDMs were labeled for 1 hour with primary antibodies diluted in PBS/1% FCS, washed and labeled again with Alexa Fluor secondary antibodies for 1 hour. Cells were washed in PBS/1% FCS and stained with DAPI in PBS for 20 minutes. Labeled cells were detected using Hermes WiScan automated cell-imaging system (IDEA Bio-Medical Ltd. Rehovot, Israel) and analyzed using MetaMorph and ImageJ software. On average 10^4^ cells were recorded and analyzed in each experiment.

### Phagocytosis assay using pHrodo Bioparticles {#sec4.4.6}

MDM were exposed to 0.25ug pHrodo (a pH-sensitive, rhodamine-based dye)-labeled *E. coli* for 1h. MDM were washed 3x in PBS and fixed. The percentage of *E.coli* positive cells was determined using Hermes WiScan automated cell-imaging system (IDEA Bio-Medical Ltd. Rehovot, Israel) and analyzed using MetaMorph and ImageJ software. 10^4^ cells were recorded and analyzed.

### ELISA {#sec4.4.7}

Medium was collected and cytokine levels quantified by ELISA (BD Biosciences) according to the manufacturer's instructions.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

We have included number of replicates (equal to number of different donors), statistical tests, and significance criteria in figure legends and in the main text of the manuscript.

Statistical analysis was performed in Excel. We used the paired t test to determine significant differences. Following P values were considered as significant: ^∗∗∗^P value ≤ *0.001, ^∗∗^P-*value ≤ 0.01, *^∗^P-*value ≤ 0.1

Data and Code Availability {#sec4.6}
--------------------------

This study did not generate any datasets.

Supplemental Information {#app2}
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Document S1. Figures S1--S4 and Table S1Document S2. Article plus Supplemental Information
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